Your session is about to expire
← Back to Search
Monoclonal Antibodies
PF-07260437 for Solid Tumors (C4431001 Trial)
Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through up to 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a special protein treatment to help the immune system target and destroy cancer cells in adults with advanced breast, ovarian, or endometrial cancer. The treatment works by connecting immune cells to cancer cells, making it easier for the immune system to attack the cancer.
Eligible Conditions
- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Ovarian Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with dose limiting toxicities (DLTs) in Dose escalation
Secondary study objectives
Accumulation Ratio (Rac)
Apparent Oral Clearance (CL/F)
Apparent Oral Clearance of Study Drug (CLss/F)
+18 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Monotherapy dose escalation (Part 1)Experimental Treatment1 Intervention
Participants will receive PF-07260437
Group II: Dose Expansion (Part 2C) - Tumor specific Arm CExperimental Treatment2 Interventions
Participants will receive PF07260437
Group III: Dose Expansion (Part 2B) - Tumor specific Arm BExperimental Treatment2 Interventions
Participants will receive PF-07260437
Group IV: Dose Expansion (Part 2A) - Tumor specific Arm AExperimental Treatment2 Interventions
Participants will receive PF-07260437
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,658 Previous Clinical Trials
17,877,257 Total Patients Enrolled
114 Trials studying Breast Cancer
41,346 Patients Enrolled for Breast Cancer
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,544 Previous Clinical Trials
14,918,433 Total Patients Enrolled
46 Trials studying Breast Cancer
17,754 Patients Enrolled for Breast Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have histological diagnosis of locally advanced or metastatic triple negative breast cancer with high B7-H4 expression.You have histological/cytological diagnosis of breast cancer, endometrial cancer or ovarian cancer.
Research Study Groups:
This trial has the following groups:- Group 1: Monotherapy dose escalation (Part 1)
- Group 2: Dose Expansion (Part 2C) - Tumor specific Arm C
- Group 3: Dose Expansion (Part 2A) - Tumor specific Arm A
- Group 4: Dose Expansion (Part 2B) - Tumor specific Arm B
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger